Lilly to Partner with Adocia in Developing BioChaperone Insulin Lispro

Eli Lilly has announced they are partnering with Adocia in a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, which is currently in Phase Ib studies.